CAMBRIDGE ANTIBODY TECHNOLOGY (CAT) ANNOUNCES MANAGEMENT APPOINTMENTS

Cambridge, UK & Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) is delighted to announce two appointments to the key management position of Vice President (VP).

Catherine Connolly joins the Company as VP Human Resources (HR) and will take up a position on CAT's Executive Group. Previously, Catherine was Interim HR Advisor for Simpay, a mobile phone payments company co-founded by Vodafone, T-mobile, Orange and Telefonica. Prior to this, she held a number of HR positions at Mediaedge:cia, KPMG and National Westminster Bank. Catherine has an MA in Law from Trinity College Dublin and a Post Graduate Diploma in HR Management from Southbank University.

Dr Kathy Lambert joins CAT as VP Quality, responsible for developing Quality strategy and ensuring GXP compliance (Good Manufacturing Practice, Good Clinical Practice and Good Laboratory Practice) within the Company's regulated environment. Previously, Kathy was Director Quality and Regulatory Affairs for Xenova Research (previously Cantab) and, prior to this, held the position of Director of UK Operations/FDA Responsible Head at Celltech Biologics (now Lonza). Kathy has over 20 years experience in the biopharmaceutical industry. Having originally qualified as a BSc nutritionist from the University of London, she also has a PhD in microbiology from the University of London and an MBA from the Open Business School.

-ENDS-

Cambridge Antibody Technology (CAT):
CAT is a UK-based biotechnology company using its proprietary technologies and capabilities in human monoclonal antibodies for drug discovery and drug development. Based near Cambridge, England, CAT currently employs around 290 people.

CAT is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary platform technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Companys strategy to develop a portfolio of antibody-based drugs.

HUMIRA, the leading CAT-derived antibody, isolated and optimised in collaboration with Abbott has been approved by the US Food and Drug Administration for marketing in the US and by the European Commission for marketing in the EU as a treatment for rheumatoid arthritis.

Eight further CAT-derived human therapeutic antibodies are at various stages of clinical trials. There are five candidate therapeutic antibodies in pre-clinical development.

CAT has alliances with a number of pharmaceutical and biotechnology companies to discover, develop and commercialise human monoclonal antibody-based products. CAT has co-development programmes with Amgen, Amrad, Elan and Genzyme.

CAT has also licensed its proprietary technologies to several companies. CATs licensees include: Abbott, Amgen, Chugai, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.

CAT is listed on the London Stock Exchange and on NASDAQ since June 2001. CAT raised £41m in its IPO in March 1997 and £93m in a secondary offering in March 2000.

Application of the Safe Harbor of the Private Securities Litigation Reform Act of 1995: This press release contains statements about Cambridge Antibody Technology Group plc ("CAT") that are forward looking statements. All statements other than statements of historical facts included in this press release may be forward looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward looking statements are based on numerous assumptions regarding the companys present and future business strategies and the environment in which the company will operate in the future. Certain factors that could cause the companys actual results, performance or achievements to differ materially from those in the forward looking statements include: market conditions, CATs ability to enter into and maintain collaborative arrangements, success of product candidates in clinical trials, regulatory developments and competition. We caution investors not to place undue reliance on the forward looking statements contained in this press release. These statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

-- 
Rob Ballantine
Communications Department

Cambridge Antibody Technology
Milstein Building 
Granta Park
Cambridge 
CB1 6GH 
UK
Telephone: + 44 (0) 1223 471471
Facsimile + 44 (0) 1223 471472
E-mail: mailto: rob.ballantine@cambridgeantibody.com
http://www.cambridgeantibody.com

Cambridge Antibody Technology Limited *
Registered Office:
Milstein Building, Granta Park, Cambridge, CB1 6GH, UK Registered in England and Wales number 2451177
(* Cambridge Antibody Technology Limited is a member of the Cambridge Antibody Technology Group of Companies)
For further information contact:

Cambridge Antibody Technology
Tel: +44 (0) 1223 471 471
Peter Chambré, Chief Executive Officer
John Aston, Chief Financial Officer
Rowena Gardner, Director of Corporate Communications

Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 20 7067 0700
Rachel Lankester
Kevin Smith

BMC Communications/The Trout Group (USA)
Tel: 001 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext 15 (investors)